Mayo Clinic Receives Patent for New Treatment of Chronic Sinus Infection

Mayo Clinic yesterday received broad patent coverage for a new treatment of chronic rhinosinusitis (CRS), commonly called “sinus infection,” a disease that annually affects 32 million adults in the United States and currently has no Food and Drug Administration-approved treatment. Studies at Mayo Clinic have found the cause of CRS — a reaction to certain fungi — and demonstrated that the delivery of antifungal drugs directly into the nose and sinuses is safe and significantly reduces patients? symptoms. Improvements in asthma symptoms were noted in the same patient group. Past medical treatments for chronic sinus infections have been unsuccessful or produced severe side effects.

Plague vaccine elicits 100% response in mice

A Canadian biomedical company said it has confirmed that a nasal vaccine protects mice against pneumonic Plague caused by lethal aerosol infection. In a series of experiments performed by the US Army Medical and Materiel Command at Fort Detrick, Maryland, in collaboration with ID Biomedical, mice nasally immunized with Plague antigen formulated with the Proteosome technology were completely protected against lethality (100%) even when the dose of Plague antigen was ten-fold lower than ever previously given nasally. In marked contrast, none of the control mice given nasal solution without vaccine antigen survived.